Takeda Oncology
Ranjana Chakravarthy is an accomplished professional in the field of market research and strategic insights, currently serving as Associate Director of Global Oncology at Takeda Oncology since April 2025. Prior to this role, Ranjana held various positions within Takeda, including Associate Director for Market Research and Competitive Intelligence in Rare Diseases and Senior Manager roles focusing on Hematology and Lysosomal Storage Disorders. Ranjana's experience also includes managing public affairs at Alexion Pharmaceuticals, as well as strategic projects at GLG and the Tufts Center for the Study of Drug Development. Ranjana holds a Bachelor's degree in Psychology from Boston University, obtained in 2013.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.